The Sino-Western Medicine Combined Treatment of Chronic Liver Disease Academic Conference of the Liver Disease Drug Research Professional Committee of the China Chinese Medicine Association concluded successfully. Mr. Xiong Yigang, Chairman of Ruihe Pharmaceutical Group, delivered an important speech at the opening ceremony.

Good morning, everyone!

I am Xiong Yigang, Chairman of Ruhe Pharmaceutical Group. Time flies. Before 2019, the scene of the establishment of the Liver Disease Drug Research Professional Committee in Beijing is still vivid in my memory. Today, we are gathered in Guiyang again. I am very happy to see many old friends and meet many new friends. I am even happier to see the growth and development of our Liver Disease Drug Research Professional Committee. First of all, on behalf of Ruhe Pharmaceutical Group, I would like to extend my warmest welcome and heartfelt gratitude to all the leaders, experts, and scholars who have attended this conference!

Guiyang, a beautiful city known as the "Summer Resort Capital," is not only famous for its cool and pleasant climate, but also for its profound cultural heritage and unique humanistic charm. I believe that during the upcoming academic exchange, everyone will not only gain wisdom and inspiration but also experience the unique charm of this land.

This conference brings together many talented individuals to participate in this grand event. We will focus on major liver disease areas such as viral hepatitis, alcoholic liver disease, fatty liver disease, and liver malignancies, and delve into the latest progress in the combined treatment of traditional Chinese and Western medicine and breakthroughs in drug research. As a deep cultivator in the field of liver disease medication, Ruhe Pharmaceutical has always adhered to the concept of "inheriting the essence and upholding innovation," empowering the millennial wisdom of traditional Chinese medicine with modern technology. Of particular note is the upcoming release of the results of the "Clinical Study on the Efficacy and Safety of Shuganning Injection in the Treatment of Liver Damage in Chronic Hepatitis B." This study has pioneered the provision of high-level evidence-based medicine for Chinese medicine injections, not only setting a new industry benchmark but also interpreting the necessity and scientific nature of the integration of traditional and modern medicine.

However, we are well aware that the journey to protect human health is endless. Ruhe Pharmaceutical will continue to increase R&D investment, deepen research on the prevention and treatment of acute and chronic liver diseases, and promote the modernization of traditional Chinese medicine. We firmly believe that only by activating traditional treasures through technological innovation and embracing modern medicine with openness and inclusiveness can traditional Chinese medicine shine brightly in the great cause of human health.

Fellow colleagues, every bit of progress in the prevention and treatment of liver disease embodies the wisdom of the experts and scholars present, and is inseparable from the sincere cooperation of various sectors in production, academia, and research. Looking to the future, we look forward to working hand in hand with you to jointly write a new chapter in the innovative development of traditional Chinese medicine, bringing more blessings to liver disease patients worldwide, and contributing more to the cause of human health.

Finally, I sincerely wish the conference a fruitful outcome! May you all be inspired by the collision of ideas, gain medical progress and friendship through academic exchanges, and experience the beauty of life amidst the beautiful mountains and rivers of Guizhou. Thank you!